CA
CRSP icon

Cetera Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Cetera Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$334K Buy
+4,900
New +$351K ﹤0.01% 1866

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Advisors's CRSP Position: Q1 2024 in Review

Cetera Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q1 2024: 4,900 shares worth $334K. The stake represents ﹤0.01% of the portfolio and ranks #1866 among its holdings.

484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Cetera Advisors held 4,900 shares of CRISPR Therapeutics worth $334K as of Q1 2024.
  • CRISPR Therapeutics was a new Cetera Advisors position in Q1 2024.
  • CRISPR Therapeutics made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1866 holding.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.